Brain imaging in dementia

Postgraduate Medical Journal

Volumn 92, Issue 1088, 2016, Pages 333-340

  Bonifacio, Guendalina ^a,b   Zamboni, Giovanna ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN; IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; BRAIN MAPPING; CLASSIFICATION; DEMENTIA; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; HUMAN; PROCEDURES; REPRODUCIBILITY;

BRAIN; BRAIN MAPPING; DEMENTIA; DIAGNOSIS, DIFFERENTIAL; HUMANS; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY; REPRODUCIBILITY OF RESULTS;

EID: 84977924503     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/postgradmedj-2015-133759     Document Type: Review

References (100)

1. Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol 2011;7:137–52.
2. Whitwell JL, Josephs KA, Murray ME, et al. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology 2008;71:743–9.
3. Vemuri P, Whitwell JL, Kantarci K, et al. Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. Neuroimage 2008;42:559–67.
4. Ridha BH, Anderson VM, Barnes J, et al. Volumetric MRI and cognitive measures in Alzheimer disease: comparison of markers of progression. J Neurol 2008;255:567–74.
5. Buckner RL, Andrews-Hanna JR, Schacter DL. The brain’s default mode network: anatomy, function, and relevance to disease. Ann N Y Acad Sci 2008;1124:1–38.
6. Gusnard DA, Raichle ME, Raichle ME. Searching for a baseline: functional imaging and the resting human brain. Nat Rev Neurosci 2001;2:685–94.
7. Fox MD, Raichle ME. Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging. Nat Rev Neurosci 2007;8:700–11.
8. Johnson KA, Fox NC, Sperling RA, et al. Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med 2012;2:a006213.
9. Davison CM, O’Brien JT. A comparison of FDG-PET and blood flow SPECT in the diagnosis of neurodegenerative dementias: a systematic review. Int J Geriatr Psychiatry 2014;29:551–61.
10. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from The National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7:263–9.
11. Goedert M, Klug A, Crowther RA. Tau protein, the paired helical filament and Alzheimer’s disease. J Alzheimers Dis 2006;9(3 Suppl):195–207.
12. Teipel SJ, Flatz WH, Heinsen H, et al. Measurement of basal forebrain atrophy in Alzheimer’s disease using MRI. Brain 2005;128:2626–44.
13. Ashburner J, Friston KJ. Voxel-based morphometry—the methods. Neuroimage 2000;11(Pt 1):805–21.
14. Busatto GF, Diniz BS, Zanetti MV. Voxel-based morphometry in Alzheimer’s disease. Expert Rev Neurother 2008;8:1691–702.
15. Braak H, Braak E, Bohl J, et al. Evolution of Alzheimer’s disease related cortical lesions. J Neural Transm Suppl 1998;54:97–106.
16. de Leon MJ, Convit A, Wolf OT, et al. Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET). Proc Natl Acad Sci USA 2001;98:10966–71.
17. Gibson GE. Interactions of oxidative stress with cellular calcium dynamics and glucose metabolism in Alzheimer’s disease. Free Radical Biol Med 2002;32:1061–70.
18. Foster NL, Chase TN, Fedio P, et al. Alzheimer’s disease: focal cortical changes shown by positron emission tomography. Neurology 1983;33:961–5.
19. Chase TN, Foster NL, Fedio P, et al. Regional cortical dysfunction in Alzheimer’s disease as determined by positron emission tomography. Ann Neurol 1984;15 (Suppl):S170–4.
20. Furst AJ, Rabinovici GD, Rostomian AH, et al. Cognition, glucose metabolism and amyloid burden in Alzheimer’s disease. Neurobiol Aging 2012;33:215–25.
21. Hoffman JM, Welsh-Bohmer KA, Hanson M, et al. FDG PET imaging in patients with pathologically verified dementia. J Nucl Med 2000;41:1920–8.
22. Mosconi L, Pupi A, De Leon MJ. Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer’s disease. Ann N Y Acad Sci 2008;1147:180–95.
23. Herholz K, Salmon E, Perani D, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 2002;17:302–16.
24. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306–19.
25. Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008;29: 1456–65.
26. Koivunen J, Pirttilä T, Kemppainen N, et al. PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment. Dement Geriatr Cogn Disord 2008;26:378–83.
27. Okello A, Koivunen J, Edison P, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 2009;73:754–60.
28. Wolk DA, Price JC, Saxton JA, et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 2009;65:557–68.
29. Jagust WJ, Bandy D, Chen K, et al. The Alzheimer’s Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement 2010;6:221–9.
30. Villemagne VL, Okamura N. Tau imaging in the study of ageing, Azheimer’s disease and other neurodegenerative conditions. Curr Opin Neurobiol 2016;36:43–51.
31. Rombouts SA, Barkhof F, Veltman DJ, et al. Functional MR imaging in Alzheimer’s disease during memory encoding. AJNR Am J Neuroradiol 2000;21:1869–75.
32. Johnson NA, Jahng GH, Weiner MW, et al. Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology 2005;234:851–9.
33. Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer’s disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005;25:7709–17.
34. Zamboni G, Wilcock GK, Douaud G, et al. Resting functional connectivity reveals residual functional activity in Alzheimer’s disease. Biol Psychiatry 2013;74:375–83.
35. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303–8.
36. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from The National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7:270–9.
37. Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia—meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand 2009;119:252–65.
38. Geslani DM, Tierney MC, Herrmann N, et al. Mild cognitive impairment: an operational definition and its conversion rate to Alzheimer’s disease. Dement Geriatr Cogn Disord 2005;19:383–9.
39. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol 2010;9:119–28.
40. Hämäläinen A, Tervo S, Grau-Olivares M, et al. Voxel-based morphometry to detect brain atrophy in progressive mild cognitive impairment. Neuroimage 2007;37:1122–31.
41. Karas GB, Scheltens P, Rombouts SARB, et al. Global and local gray matter loss in mild cognitive impairment and Alzheimer’s disease. Neuroimage 2004;23:708–16.
42. Jack CR Jr., Petersen RC, Xu Y, et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology 2000;55:484–9.
43. Jack CR Jr., Weigand SD, Shiung MM, et al. Atrophy rates accelerate in amnestic mild cognitive impairment. Neurology 2008;70(Pt 2):1740–52.
44. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 2005;32:486–510.
45. Jack CR Jr., Lowe VJ, Weigand SD, et al. Alzheimer’s Disease Neuroimaging Initiative. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: implications for sequence of pathological events in Alzheimer’s disease. Brain 2009;132(Pt 5):1355–65.
46. Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008;29:1456–65.
47. Pike KE, Savage G, Villemagne VL, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer’s disease. Brain 2007;130(Pt 11):2837–44.
48. Fjell AM, Westlye LT, Amlien I, et al. High-expanding cortical regions in human development and evolution are related to higher intellectual abilities. Cereb Cortex 2015;25:26–34.
49. Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010;67:122–31.
50. Dickerson BC, Sperling RA. Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer’s disease. NeuroRx 2005;2:348–60.
51. Matthews FE, Brayne C, Lowe J, et al. Epidemiological pathology of dementia: attributable-risks at death in the Medical Research Council Cognitive Function and Ageing Study. PLoS Med 2009;6:e1000180.
52. Schneider JA, Arvanitakis Z, Bang W, et al. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007;69:2197–204.
53. Román GC. Facts, myths, and controversies in vascular dementia. J Neurol Sci 2004;226:49–52.
54. Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:2672–713.
55. Sachdev P, Kalaria R, O’Brien J, et al. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord 2014;28:206–18.
56. Wardlaw J, Smith C, Dichgans M. Microbleeds in cerebral small vessel disease— authors’ reply. Lancet Neurol 2013;12:736–7.
57. Du AT, Schuff N, Laakso MP, et al. Effects of subcortical ischemic vascular dementia and AD on entorhinal cortex and hippocampus. Neurology 2002;58:1635–41.
58. de Laat KF, Tuladhar AM, van Norden AG, et al. Loss of White matter integrity is associated with gait disorders in cerebral small vessel disease. Brain 2011;134(Pt 1):73–83.
59. Inzitari D, Pracucci G, Poggesi A, et al. Changes in White matter as determinant of global functional decline in older independent outpatients: three year follow-up of LADIS (leukoaraiosis and disability) study cohort. BMJ 2009;339:b2477.
60. Debette S, and Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ 2010;341:c3666.
61. Frisoni GB, Galluzzi S, Pantoni L, et al. The effect of white matter lesions on cognition in the elderly—small but detectable. Nat Clin Pract Neurol 2007;3:620–7.
62. Lee AY. Vascular dementia. Chonnam Med J 2011;47:66–71.
63. Koga H, Takashima Y, Murakawa R, et al. Cognitive consequences of multiple lacunes and leukoaraiosis as vascular cognitive impairment in community-dwelling elderly individuals. J Stroke Cerebrovasc Dis 2009;18:32–7.
64. Benisty S, Gouw AA, Porcher R, et al. Location of lacunar infarcts correlates with cognition in a sample of non-disabled subjects with age-related White-matter changes: the LADIS study. J Neurol Neurosurg Psychiatry 2009;80:478–83.
65. Vermeer SE, Longstreth WT Jr., Koudstaal PJ. Silent brain infarcts: a systematic review. Lancet Neurol 2007;6:611–19.
66. Werring DJ, Frazer DW, Coward LJ, et al. Cognitive dysfunction in patients with cerebral microbleeds on T2*-weighted gradient-echo MRI. Brain 2004;127(Pt 10):2265–75.
67. Brundel M, Kwa VI, Bouvy WH, et al. Cerebral microbleeds are not associated with long-term cognitive outcome in patients with transient ischemic attack or minor stroke. Cerebrovasc Dis 2014;37:195–202.
68. Eckerström C, Olsson E, Klasson N, et al. High White matter lesion load is associated with hippocampal atrophy in mild cognitive impairment. Dement Geriatr Cogn Disord 2011;31:132–8.
69. Allen N, Berry JD, Ning H, et al. Impact of blood pressure and blood pressure change during middle age on the remaining lifetime risk for cardiovascular disease: the cardiovascular lifetime risk pooling project. Circulation 2012;125:37–44.
70. Patel B, Markus HS. Magnetic resonance imaging in cerebral small vessel disease and its use as a surrogate disease marker. Int J Stroke 2011;6:47–59.
71. Brickman AM, Provenzano FA, Muraskin J, et al. Regional white matter hyperintensity volume, not hippocampal atrophy, predicts incident Alzheimer disease in the community. Arch Neurol 2012;69:1621–7.
72. Nitkunan A, Barrick TR, Charlton RA, et al. Multimodal MRI in cerebral small vessel disease: its relationship with cognition and sensitivity to change over time. Stroke 2008;39:1999–2005.
73. Grafton ST, Sumi SM, Stimac GK, et al. Comparison of postmortem magnetic resonance imaging and neuropathologic findings in the cerebral white matter. Arch Neurol 1991;48:293–8.
74. Korczyn AD, Vakhapova V, Grinberg LT. Vascular dementia. J Neurol Sci 2012;322:2–10.
75. Beeri MS, Ravona-Springer R, Silverman JM, et al. The effects of cardiovascular risk factors on cognitive compromise. Dialogues Clin Neurosci 2009;11:201–12.
76. Lockhart SN, Luck SJ, Geng J, et al. White matter hyperintensities among older adults are associated with futile increase in frontal activation and functional connectivity during spatial search. PLoS ONE 2015;10:e0122445.
77. Schaefer A, Quinque EM, Kipping JA, et al. Early small vessel disease affects frontoparietal and cerebellar hubs in close correlation with clinical symptoms—a resting-state fMRI study. J Cereb Blood Flow Metab 2014;34:1091–5.
78. Kirshner HS. Frontotemporal dementia and primary progressive aphasia, a review. Neuropsychiatr Dis Treat 2014;10:1045–55.
79. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51:1546–54.
80. Rosen HJ, Allison SC, Schauer GF, et al. Neuroanatomical correlates of behavioural disorders in dementia. Brain 2005;128(Pt 11):2612–25.
81. Rosen HJ, Gorno-Tempini ML, Goldman WP, et al. Patterns of brain atrophy in frontotemporal dementia and semantic dementia. Neurology 2002;58:198–208.
82. Seeley WW, Crawford RK, Zhou J, et al. Neurodegenerative diseases target large-scale human brain networks. Neuron 2009;62:42–52.
83. Gorno-Tempini ML, Dronkers NF, Rankin KP, et al. Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol 2004;55:335–46.
84. Rohrer JD, Ridgway GR, Crutch SJ, et al. Progressive logopenic/phonological aphasia: erosion of the language network. Neuroimage 2010;49:984–93.
85. McKeith L, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113–24.
86. Collerton D, Burn D, McKeith I, et al. Systematic review and meta-analysis show that dementia with Lewy bodies is a visual-perceptual and attentional-executive dementia. Demen Geriatr Cogn Disord 2003;16:229–37.
87. Sabattoli F, Boccardi M, Galluzzi S, et al. Hippocampal shape differences in dementia with Lewy bodies. Neuroimage 2008;41:699.
88. Kantarci K, Ferman TJ, Boeve BF, et al. Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies. Neurology 2012;79:553–6010.
89. Bozzali M, Falini A, Cercignani M, et al. Brain tissue damage in dementia with Lewy bodies: an in vivo diffusion tensor MRI study. Brain 2005;128(Pt 7):1595–604.
90. Mak E, Su L, Williams GB, et al. Neuroimaging characteristics of dementia with Lewy bodies. Alzheimers Res Ther 2014;6:18.
91. Albin RL, Minoshima S, D’Amato CJ, et al. Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology 1996;47:462–610.
92. Gomperts SN, Rentz DM, Moran E, et al. Imaging amyloid deposition in Lewy body diseases. Neurology 2008;71:903–10.
93. Donaghy P, Thomas AJ, O’Brien JT. Amyloid PET imaging in Lewy body disorders. Am J Geriatr Psychiatry 2015;23:23–37.
94. Kenny ER, Blamire AM, Firbank MJ, et al. Functional connectivity in cortical regions in dementia with Lewy bodies and Alzheimer’s disease. Brain 2012;135:569–81.
95. Sorbi S, Hort J, Erkinjuntti T, et al. EFNS-ENS guidelines on the diagnosis and management of disorders associated with dementia. Eur J Neurol 2012;19:1159–79.
96. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863–72.
97. Jack CR, Barkhof F, Bernstein MA, et al. Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer’s disease. Alzheimers Dement 2011;7:474–485.e4 e474.
98. Bermingham SL. The appropriate use of neuroimaging in the diagnostic work-up of dementia. Ont Health Technol Assess Ser 2014;14:1–67.
99. Silverman DH, Gambhir SS, Huang HW, et al. Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefits. J Nucl Med 2002;43:253–66.
100. Wollman DE, Beeri MS, Weinberger M, et al. Tolerance of MRI procedures by the oldest old. Magn Reson Imaging 2004;22:1299–304.